These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

345 related items for PubMed ID: 12759734

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Successful treatment of cutaneous leishmaniasis with amphotericin B; a case of unresponsive to pentavalent antimony therapy].
    Yeşilova Y, Turan E, Sürücü HA, Aksoy M, Özbilgin A.
    Turkiye Parazitol Derg; 2015 Mar; 39(1):63-5. PubMed ID: 25917587
    [Abstract] [Full Text] [Related]

  • 3. Comparison of in vitro Resistance of Wild Leishmania İsolates, Which are Resistant to Pentavalent Antimonial Compounds, Against Drugs Used in the Treatment of Leishmaniasis.
    Özbilgin A, Çavuş İ, Kaya T, Yıldırım A, Harman M.
    Turkiye Parazitol Derg; 2020 Mar 20; 44(1):12-16. PubMed ID: 32212583
    [Abstract] [Full Text] [Related]

  • 4. Cutaneous leishmaniasis.
    Hepburn NC.
    Clin Exp Dermatol; 2000 Jul 20; 25(5):363-70. PubMed ID: 11012586
    [Abstract] [Full Text] [Related]

  • 5. [Treatment of localized cutaneous leishmaniasis].
    Buffet P, Caumes E, Gentilini M.
    Ann Dermatol Venereol; 1994 Jul 20; 121(6-7):503-11. PubMed ID: 7702288
    [No Abstract] [Full Text] [Related]

  • 6. Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis.
    Moosavi Z, Nakhli A, Rassaii S.
    Int J Dermatol; 2005 Dec 20; 44(12):1064-5. PubMed ID: 16409282
    [No Abstract] [Full Text] [Related]

  • 7. Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major.
    Shazad B, Abbaszadeh B, Khamesipour A.
    Eur J Dermatol; 2005 Dec 20; 15(2):85-7. PubMed ID: 15757817
    [Abstract] [Full Text] [Related]

  • 8. New delivery strategies for the old pentavalent antimonial drugs.
    Frézard F, Demicheli C.
    Expert Opin Drug Deliv; 2010 Dec 20; 7(12):1343-58. PubMed ID: 21029028
    [Abstract] [Full Text] [Related]

  • 9. Cutaneous leishmaniasis: an overview.
    Hepburn NC.
    J Postgrad Med; 2003 Dec 20; 49(1):50-4. PubMed ID: 12865571
    [Abstract] [Full Text] [Related]

  • 10. Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study.
    Soto J, Fuya P, Herrera R, Berman J.
    Clin Infect Dis; 1998 Jan 20; 26(1):56-8. PubMed ID: 9455509
    [Abstract] [Full Text] [Related]

  • 11. Cutaneous leishmaniasis treatment.
    Minodier P, Parola P.
    Travel Med Infect Dis; 2007 May 20; 5(3):150-8. PubMed ID: 17448941
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: A systematic review.
    Brito NC, Rabello A, Cota GF.
    PLoS One; 2017 May 20; 12(9):e0184777. PubMed ID: 28926630
    [Abstract] [Full Text] [Related]

  • 13. Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment of American cutaneous leishmaniasis: controlled study.
    Krause G, Kroeger A.
    Clin Infect Dis; 1999 Aug 20; 29(2):466-7. PubMed ID: 10476776
    [No Abstract] [Full Text] [Related]

  • 14. Leishmaniasis: an update of current pharmacotherapy.
    Sundar S, Chakravarty J.
    Expert Opin Pharmacother; 2013 Jan 20; 14(1):53-63. PubMed ID: 23256501
    [Abstract] [Full Text] [Related]

  • 15. Recent advances in the treatment of visceral leishmaniasis.
    Davidson RN, Croft SL.
    Trans R Soc Trop Med Hyg; 1993 Jan 20; 87(2):130-1, 141. PubMed ID: 8393221
    [No Abstract] [Full Text] [Related]

  • 16. Treatment of Old World cutaneous leishmaniasis with intralesionally injected meglumine antimoniate using a Dermojet device.
    Bogenrieder T, Lehn N, Landthaler M, Stolz W.
    Dermatology; 2003 Jan 20; 206(3):269-72. PubMed ID: 12673089
    [Abstract] [Full Text] [Related]

  • 17. Visceral leishmaniasis in paediatrics.
    Kafetzis DA, Maltezou HC.
    Curr Opin Infect Dis; 2002 Jun 20; 15(3):289-94. PubMed ID: 12015464
    [Abstract] [Full Text] [Related]

  • 18. Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patients.
    Minodier P, Retornaz K, Horelt A, Garnier JM.
    Fundam Clin Pharmacol; 2003 Apr 20; 17(2):183-8. PubMed ID: 12667228
    [Abstract] [Full Text] [Related]

  • 19. Leishmaniasis.
    Herwaldt BL.
    Lancet; 1999 Oct 02; 354(9185):1191-9. PubMed ID: 10513726
    [Abstract] [Full Text] [Related]

  • 20. Liposomal amphotericin B in comparison to sodium stibogluconate for cutaneous infection due to Leishmania braziliensis.
    Solomon M, Baum S, Barzilai A, Scope A, Trau H, Schwartz E.
    J Am Acad Dermatol; 2007 Apr 02; 56(4):612-6. PubMed ID: 17276541
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.